Low Bioavailability and High Immunogenicity of a New Brand of E. coli L-Asparaginase with Active Host Contaminating Proteins

The drug L-asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL). The native E. coli L-asparaginase used in Brazil until recently has been manufactured by Medac/Kyowa. Then a decision was taken by the Ministry of Health in 2017 to supply the National Health System with a cheaper alternative L-asparaginase manufactured by Beijing SL Pharmaceutical, called Leuginase (R). As opposed to Medac, the asparaginase that has been in use in Brazil under the trade name of Aginasa (R), it was not possible to find a single entry with the terms Leuginase in the Pubmed repository. The apparent lack of clinical studies and the scarcity of safety information provided to the hospitals by the drug distributor created a debate among Brazilian pediatric oncologists about issues of safety and efficacy that culminated eventually in a court decision to halt the distribution of the new drug all over the country. Boldrini Children's Center, a non-profit pediatric oncohematology hospital, has conducted its own evaluation of Leuginase (R). Mass spectrometry analyses found at least 12 different contaminating host-cell proteins (HCP) in Leuginase (R). The presence of two HCP (beta-lactamase and malate dehydrogenase) was confirmed by orthogonal methodologies. The relative number of HCP peptides ranged from 19 to 37% of the total peptides identified by mass spectrometry. In vivo studies in mice injected with Leuginase (R) revealed a 3 times lower plasma bioavailability and the development of higher antibody titres against L-asparaginase in comparison to Aginasa (R)-injected animals. The decision to buy a new drug based on its price alone is not safe. Developing countries are especially vulnerable to cheaper alternatives that lack solid quality assurance. (C) 2018 The Authors. Published by Elsevier B.V.